| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:2257.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
From the Cardiovascular Medicine and Gene Therapy Section, National Laboratory of the National Institute of Biostructures and Biosystems, Osilo; Department of Internal Medicine (P.M.), University of Sassari; and Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy.
Correspondence to Costanza Emanueli, PhD, Cardiovascular Medicine and Gene Therapy Section, INBB National Laboratory, viale SantAntonio, 07033 Osilo, Sassari, Italy. E-mail emanueli{at}yahoo.com
Background The neurotrophin nerve growth factor (NGF) regulates neuron survival and differentiation. Implication in neovascularization is supported by statement of NGF and its high-affinity receptor at vascular level and by NGF property of stimulating vascular endothelial cell proliferation. The present study investigated the involvement of endogenous NGF in spontaneous reparative response to ischemia. Mechanisms and therapeutic potential of NGF-induced neovascularization were examined.
Methods and Results Unilateral limb ischemia was produced in CD1 mice by femoral artery resection. By ELISA and immunohistochemistry, we documented that statement of NGF and its high-affinity receptor is upregulated in ischemic muscles. The functional relevance of this phenomenon was assessed by means of NGF-neutralizing antibody. Chronic NGF blockade abrogated the spontaneous capillarization response to ischemia and augmented myocyte apoptosis. Then we tested whether NGF administration may exert curative effects. Repeated NGF injection into ischemic adductors increased capillary and arteriole density, reduced endothelial cell and myofiber apoptosis, and accelerated perfusion recovery, without altering systemic hemodynamics. In normoperfused muscles, NFG-induced capillarization was blocked by vascular endothelial growth factorneutralizing antibodies, dominant-negative Akt, or NO synthase inhibition.
Conclusions These results indicate that NGF plays a functional role in reparative neovascularization. Furthermore, supplementation of the growth factor promotes angiogenesis through a vascular endothelial growth factor-Akt-NOmediated mechanism. In the setting of ischemia, potentiation of NGF pathway stimulates angiogenesis and arteriogenesis, thereby accelerating hemodynamic recovery. NGF might be envisaged as a utilitarian target for the treatment of ischemic vascular disease.
Key Words: angiogenesis ischemia muscles
This article has been cited by other articles:
![]() |
J. Xing, J. Lu, and J. Li Contribution of nerve growth factor to augmented TRPV1 responses of muscle sensory neurons by femoral artery occlusion Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1380 - H1387. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-O. Jeong, M.-O. Kim, H. Kim, M.-Y. Lee, S.-W. Kim, M. Ii, J.-u. Lee, J. Lee, Y. J. Choi, H.-J. Cho, et al. Dual Angiogenic and Neurotrophic Effects of Bone Marrow-Derived Endothelial Progenitor Cells on Diabetic Neuropathy Circulation, February 10, 2009; 119(5): 699 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Caporali and C. Emanueli Cardiovascular Actions of Neurotrophins Physiol Rev, January 1, 2009; 89(1): 279 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Caporali, E. Pani, A. J.G. Horrevoets, N. Kraenkel, A. Oikawa, G. B. Sala-Newby, M. Meloni, B. Cristofaro, G. Graiani, A. S. Leroyer, et al. Neurotrophin p75 Receptor (p75NTR) Promotes Endothelial Cell Apoptosis and Inhibits Angiogenesis: Implications for Diabetes-Induced Impaired Neovascularization in Ischemic Limb Muscles Circ. Res., July 18, 2008; 103(2): e15 - e26. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Spinetti, N. Kraenkel, C. Emanueli, and P. Madeddu Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies Cardiovasc Res, May 1, 2008; 78(2): 265 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. El-Helou, C. Proulx, H. Gosselin, R. Clement, A. Mimee, L. Villeneuve, and A. Calderone Dexamethasone treatment of post-MI rats attenuates sympathetic innervation of the infarct region J Appl Physiol, January 1, 2008; 104(1): 150 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zaccagnini, F. Martelli, A. Magenta, C. Cencioni, P. Fasanaro, C. Nicoletti, P. Biglioli, P. G. Pelicci, and M. C. Capogrossi p66ShcA and Oxidative Stress Modulate Myogenic Differentiation and Skeletal Muscle Regeneration after Hind Limb Ischemia J. Biol. Chem., October 26, 2007; 282(43): 31453 - 31459. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-J. Park, H.-J. Kwak, H.-C. Lee, D.-H. Yoo, I.-C. Park, M.-S. Kim, S.-H. Lee, C. H. Rhee, and S.-I. Hong Nerve Growth Factor Induces Endothelial Cell Invasion and Cord Formation by Promoting Matrix Metalloproteinase-2 Expression through the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway and AP-2 Transcription Factor J. Biol. Chem., October 19, 2007; 282(42): 30485 - 30496. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Egger, W. Schgoer, A. G. E. Beer, J. Jeschke, J. Leierer, M. Theurl, S. Frauscher, O. M. Tepper, A. Niederwanger, A. Ritsch, et al. Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1{alpha}- and basic FGF-dependent pathway in muscle cells FASEB J, September 1, 2007; 21(11): 2906 - 2917. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Invernici, C. Emanueli, P. Madeddu, S. Cristini, S. Gadau, A. Benetti, E. Ciusani, G. Stassi, M. Siragusa, R. Nicosia, et al. Human Fetal Aorta Contains Vascular Progenitor Cells Capable of Inducing Vasculogenesis, Angiogenesis, and Myogenesis in Vitro and in a Murine Model of Peripheral Ischemia Am. J. Pathol., June 1, 2007; 170(6): 1879 - 1892. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ieda, H. Kanazawa, Y. Ieda, K. Kimura, K. Matsumura, Y. Tomita, T. Yagi, T. Onizuka, K. Shimoji, S. Ogawa, et al. Nerve Growth Factor Is Critical for Cardiac Sensory Innervation and Rescues Neuropathy in Diabetic Hearts Circulation, November 28, 2006; 114(22): 2351 - 2363. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakamura, K. C. Martin, J. K. Jackson, K. Beppu, C.-W. Woo, and C. J. Thiele Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells. Cancer Res., April 15, 2006; 66(8): 4249 - 4255. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chalothorn, H. Zhang, J. A. Clayton, S. A. Thomas, and J. E. Faber Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H947 - H959. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Madeddu Therapeutic angiogenesis and vasculogenesis for tissue regeneration Exp Physiol, May 1, 2005; 90(3): 315 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Cao, A. Hong, H. Schulten, and M. J. Post Update on therapeutic neovascularization Cardiovasc Res, February 15, 2005; 65(3): 639 - 648. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tivesten, A. Barlind, K. Caidahl, N. Klintland, A. Cittadini, C. Ohlsson, and J. Isgaard Growth hormone-induced blood pressure decrease is associated with increased mRNA levels of the vascular smooth muscle KATP channel J. Endocrinol., October 1, 2004; 183(1): 195 - 202. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Heil and W. Schaper Influence of Mechanical, Cellular, and Molecular Factors on Collateral Artery Growth (Arteriogenesis) Circ. Res., September 3, 2004; 95(5): 449 - 458. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kirchmair, M. Egger, D. H. Walter, W. Eisterer, A. Niederwanger, E. Woell, M. Nagl, M. Pedrini, T. Murayama, S. Frauscher, et al. Secretoneurin, an Angiogenic Neuropeptide, Induces Postnatal Vasculogenesis Circulation, August 31, 2004; 110(9): 1121 - 1127. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kirchmair, R. Gander, M. Egger, A. Hanley, M. Silver, A. Ritsch, T. Murayama, N. Kaneider, W. Sturm, M. Kearny, et al. The Neuropeptide Secretoneurin Acts as a Direct Angiogenic Cytokine In Vitro and In Vivo Circulation, February 17, 2004; 109(6): 777 - 783. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. van Royen, J. J Piek, D. A Legemate, W. Schaper, J. Oskam, B. Atasever, M. Voskuil, D. Ubbink, S. H Schirmer, I. Buschmann, et al. Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial Vascular Medicine, August 1, 2003; 8(3): 191 - 196. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |